ORAGENICS, INC. Foreign Currency Transaction Gain (Loss), before Tax
ORAGENICS, INC. (OGEN) reported Foreign Currency Transaction Gain (Loss), before Tax of -$12.17 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-13
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$12.17K.
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$5.09K.
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$5.12K, a 178.87% decline year-over-year.
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$3.92K.
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$13.19K.
- ORAGENICS, INC. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$25.17K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.17K 10-Q · filed 2026-08-13 | -$17.26K 10-Q · filed 2026-08-13 | -$22.37K derived: sum of 3 quarters · filed 2026-08-13 | -$26.29K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$5.09K 10-Q · filed 2026-05-08 | -$10.21K derived: sum of 2 quarters · filed 2026-05-08 | -$14.13K derived: sum of 3 quarters · filed 2026-05-08 | -$16.44K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$5.12K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$9.04K derived: sum of 2 quarters · filed 2026-03-16 | -$11.35K derived: sum of 3 quarters · filed 2026-08-13 | -$13.19K 10-K · filed 2026-03-16 |
| 2025-09-30 | -$3.92K 10-Q · filed 2025-11-07 | -$6.24K derived: sum of 2 quarters · filed 2026-08-13 | -$8.08K 10-Q · filed 2025-11-07 | -$1.59K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.32K 10-Q · filed 2026-08-13 | -$4.16K 10-Q · filed 2026-08-13 | $2.33K derived: sum of 3 quarters · filed 2026-08-13 | -$22.76K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.84K 10-Q · filed 2026-05-08 | $4.64K derived: sum of 2 quarters · filed 2026-05-08 | -$20.44K derived: sum of 3 quarters · filed 2026-05-08 | -$24.13K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $6.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$18.60K derived: sum of 2 quarters · filed 2026-03-16 | -$22.29K derived: sum of 3 quarters · filed 2026-03-16 | -$25.17K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$25.09K 10-Q · filed 2025-11-07 | -$28.78K derived: sum of 2 quarters · filed 2025-11-07 | -$31.66K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$3.69K 10-Q · filed 2025-08-08 | -$6.57K 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | -$2.88K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |